Loading
Adding immunotherapy to first chemotherapy for advanced endometrial cancer extended life by more than a year on average, most dramatically in tumours with a broken DNA spell-checker.
In dMMR/MSI-H tumours, 24-month PFS was 61.4% vs 15.7% (HR 0.28); in the overall population PFS HR 0.64 (NEJM 2023). Overall survival in the overall population was 44.6 vs 28.2 months (HR 0.69; Annals of Oncology 2024), with dMMR OS HR 0.32. FDA approval July 2023 (dMMR) and August 2024 (all comers).
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
494 enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-free survival at 24 months (dMMR/MSI-H)primary | Dostarlimab + chemo | - | 61.4% | 0.28 (0.16 to 0.5) | - | link |
| Placebo + chemo | - | 15.7% | ||||
| Overall survival (overall population)primary | Dostarlimab + chemo | 245 | 44.6 months | 0.69 (0.54 to 0.89) | - | link |
| Placebo + chemo | 249 | 28.2 months |
Shares Chemotherapy + PD-1/PD-L1 blockade, first-line advanced endometrial cancer, Society of Gynecologic Oncology, GOG Foundation, Endometrial cancer with no specific molecular profile.
Shares Mansoor Raza Mirza, Uterine carcinosarcoma, Mismatch-repair-deficient endometrial cancer, Advanced or recurrent endometrial cancer.
Shares Chemotherapy + PD-1/PD-L1 blockade, first-line advanced endometrial cancer, Mismatch-repair-deficient endometrial cancer, Advanced or recurrent endometrial cancer, Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR).
Shares Mismatch-repair-deficient endometrial cancer, Advanced or recurrent endometrial cancer, Dostarlimab, Endometrial cancer.
Shares p53-abnormal endometrial cancer, including uterine serous carcinoma, Advanced or recurrent endometrial cancer, Endometrial cancer, Paclitaxel / nab-paclitaxel.
Shares Mismatch-repair-deficient endometrial cancer, Advanced or recurrent endometrial cancer, Endometrial cancer, Carboplatin.
Shares Uterine carcinosarcoma, p53-abnormal endometrial cancer, including uterine serous carcinoma, Endometrial cancer with no specific molecular profile, Mismatch-repair-deficient endometrial cancer.
Shares Uterine carcinosarcoma, p53-abnormal endometrial cancer, including uterine serous carcinoma, Endometrial cancer with no specific molecular profile, Mismatch-repair-deficient endometrial cancer.